| |
著者: Abimbola O Ajibowo, Juan Fernando Ortiz, Ammar Alli, Taras Halan, Olasunkanmi A Kolawole
雑誌名: Cureus. 2021 Apr 20;13(4):e14579. doi: 10.7759/cureus.14579. Epub 2021 Apr 20.
Abstract/Text
Japanese encephalitis (JE) continues to be one of the world's most serious infections with no definitive treatment or guidelines. The high morbidity and mortality rate among symptomatic patients warrant the need for further investigation in this regard. Our review focuses on the recent updates on Japanese encephalitis treatment. For that reason, we used an advanced PubMed search with JE and drugs like minocycline, interferon, ribavirin, immunoglobulin, dexamethasone, and acyclovir. All research was done in full papers written in the English language and conducted in humans. This review aims to compare and analyze recent papers regarding JE treatment to guide healthcare providers with the latest information and make evidence-based decisions when presented with this infection. Overall, only minocycline had promising results because one of the two studies showed statistically significant results. The second study showed positive trends in children over 12 years and patients who survived on the first day of hospitalization. The study with intravenous immunoglobulin (IVIG) did not improve the outcomes; however, it increased the levels of neutralizing antibodies. Further study with higher doses may change the outcomes in patients with JE. The other drugs failed to show promising results.
Copyright © 2021, Ajibowo et al.
PMID 34036000 Cureus. 2021 Apr 20;13(4):e14579. doi: 10.7759/cureus.14579. Epub 2021 Apr 20.
|
